The global health challenge posed by the hepatitis B virus (HBV) centres around the widespread distribution and the serious complications as a result of persistent infection with the virus. As with other chronic diseases mediated by pathogens such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV), clinicians are searching for epidemiological, pathological and viral characteristics of HBV infection that may lead to more effective management of patients with chronic infection. Unlike HCV, the role of HBV genotype in disease progression, severity, response to therapy and drug resistance is still under investigation and just beginning to be clarified. This review examines the potential role of HBV genotype determination in the clinic with emphasis on how this genetic information may used to provide effective management for the treatment of patients with chronic hepatitis B.
References
1.
LocarniniS.A.Clinical relevance of viral dynamics and genotypes in hepatitis B virus.Journal of Gastroenterology & Hepatology2002; 17 (Suppl 3): S322–S328.
2.
LeeC.M., ChenC.H., LuS.N., TungH.D., ChouW.J., WangJ.H., ChenT.M., HungC.H., HuangC.C., & ChenW.J.Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan.Scandanavian Journal of Gastroenterology2003; 38: 95–101.
3.
HipgraveD.B., NguyenT.V., VuM.H., HoangT.L., DoT.D., TranN.T., JolleyD., MaynardJ.E., & BiggsB.A.Hepatitis B infection in rural Vietnam and the implications for a national program of infant immunization.American Journal of Tropical Medicine & Hygiene2003; 69: 288–294.
4.
SouzaK.P., LuzJ.A., TelesS.A., CarneiroM.A., OliveiraL.A., GomesA.S., DiasM.A., GomesS.A., YoshidaC.F., & MartinsR.M.Hepatitis B and C in the hemodialysis unit of Tocantins, Brazil: serological and molecular profiles.Memorial Institute of Oswaldo Cruz2003; 98: 599–603.
5.
DingX., GuH., ZhongZ.H., ZilongX., TranH.T., IwakiY., LiT.C., SataT., & AbeK.Molecular epidemiology of hepatitis viruses and genotypic distribution of hepatitis B and C viruses in Harbin, China.Japanese Journal of Infectious Diseases2003; 56: 19–22.
6.
LavanchyD.Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.Journal of Viral Hepatitis2004; 11: 97–107.
7.
YounossiZ.M.Viral hepatitis guide for practicing physicians. Cleveland Clinic of Medicine.Cleveland Clinic Journal of Medicine2000; 67 (Suppl 1): S16–S45.
8.
HadziyannisS.J., & PapatheodoridisG.V.Emerging treatments in chronic hepatitis B.Expert Opinions in Emerging Drugs2004; 9: 207–221.
9.
PineiroYLFG, MbayedV.A., and CamposR.H.Evolutionary history of hepatitis B virus genotype F: an in-depth analysis of argentine isolates.Virus Genes2003; 27: 103–110.
10.
KannM.Structural and Molecular Virology. In Hepatitis B Virus, vol. 12002; pp. 9–22. Edited by LaiC-L, & LocarniniS.. London: International Medical Press.
11.
KaoJ.H.Hepatitis B viral genotypes: clinical relevance and molecular characteristics.Journal of Gastroenterology & Hepatology2002; 17: 643–650.
12.
JilbertA.R., BurrellC.J., TriatniM., & KannM.Hepatitis B virus replication. In Hepatitis B Virus, 2002, pp. 43–53. Edited by LaiC-L, & LocarniniS.. London: International Medical Press.
13.
LocarniniS., McMillanJ., & BartholomeuszA.The hepatitis B virus and common mutants.Seminars in Liver Disease2003; 23: 5–20.
14.
YoungerH.M., BathgateA.J., & HayesP.C.Review article: nucleoside analogues for the treatment of chronic hepatitis B.Alimentary Pharmacology Therapeutics2004; 20: 1211–1230.
15.
HollingerF.B., & LiangT.J.Hepatitis B virus. In Feild's Virolog, vol. 22001; 4th edn; pp. 2971–3036. Edited by KnipeD.M., & HowleyP.M.. Philadelphia: Lippincott Williams and Wilkins.
16.
DooE., & LiangT.J.Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection.Gastroenterology2001; 120: 1000–1008.
ThakurV., GuptanR.C., KazimS.N., MalhotraV., & SarinS.K.Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent.Journal of Gastroenterology & Hepatology2002; 17: 165–170.
19.
OritoE., MizokamiM., InaY., MoriyamaE.N., KameshimaN., YamamotoM., & GojoboriT.Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences.Proceedings of the National Academy of Sciences, USA1989; 86: 7059–7062.
20.
OkamotoH., ImaiM., KametaniM., NakamuraT., & MayumiM.Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission.Japanese Journal of Experimental Medicine1987; 57: 231–236.
21.
StuyverL., De GendtS., Van GeytC., ZoulimF., FriedM., SchinaziR.F., & RossauR.A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness.Journal of General Virology2000; 81: 67–74.
22.
KaoJ.H., & ChenD.S.Global control of hepatitis B virus infection.Lancet Infectious Diseases2002; 2: 395–403.
23.
OkamotoH., TsudaF., SakugawaH., SastrosoewignjoR.I., ImaiM., MiyakawaY., & MayumiM.Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes.Journal of General Virology1988; 69 (Pt 10): 2575–2583.
24.
BartholomeuszA., & SchaeferS.Hepatitis B virus genotypes: comparison of genotyping methods.Reviews in Medical Virology2004; 14: 3–16.
25.
ClarkeB., & BloorS.Molecular genotyping of hepatitis B virus.Journal of Clinical Virology2002; 25 (Suppl 3): S41–S45.
26.
CuiC., ShiJ., HuiL., XiH., Zhuoma, Quni, Tsedan, & HuG.The dominant hepatitis B virus genotype identified in Tibet is a C/D hybrid.Journal of General Virology2002; 83: 2773–2777.
27.
SugauchiF., OritoE., IchidaT., KatoH., SakugawaH., KakumuS., IshidaT., ChutaputtiA., LaiC.L., UedaR., MiyakawaY., & MizokamiM.Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene.Journal of Virology2002; 76: 5985–5992.
28.
SuzukiS., SugauchiF., OritoE., KatoH., UsudaS., SiransyL., AritaI., SakamotoY., YoshiharaN., El-GoharyA., UedaR., & MizokamiM.Distribution of hepatitis B virus (HBV) genotypes among HBV carriers in the Cote d'Ivoire: complete genome sequence and phylogenetic relatedness of HBV genotype E.Journal of Medical Virology2003; 69: 459–465.
29.
JohR., HasegawaK., OgawaM., IshikawaK., IizukaA., NaritomiT., KanaiN., ToriiN., HashimotoE., & HayashiN.Genotypic analysis of hepatitis B virus from patients with fulminant hepatitis: comparison with acute self-limited hepatitis.Hepatology Research2003; 26: 119–124.
30.
NakayoshiT., MaeshiroT., NakasoneH., SakugawaH., KinjoF., OritoE., & MizokamiM.Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands: a prospective study.Journal of Medical Virology2003; 70: 350–354.
31.
Sanchez-TapiasJ.M., CostaJ., MasA., BrugueraM., & RodesJ.Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients.Gastroenterology2002; 123: 1848–1856.
32.
HussainM., ChuC.J., SablonE., & LokA.S.Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants.Journal of Clinical Microbiology2003; 41: 3699–3705.
33.
LokA.S., ZoulimF., LocarniniS., MangiaA., NiroG., DecraemerH., MaertensG., HulstaertF., De VreeseK., & SablonE.Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.Journal of Clinical Microbiology2002; 40: 3729–3734.
34.
SumiH., YokosukaO., SekiN., AraiM., ImazekiF., KuriharaT., KandaT., FukaiK., KatoM., & SaishoH.Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease.Hepatology2003; 37: 19–26.
35.
SugauchiF., OritoE., KatoH., SuzukiS., KawakitaS., SakamotoY., FukushimaK., AkibaT., YoshiharaN., UedaR., & MizokamiM.Genotype, serotype, and phylogenetic characterization of the complete genome sequence of hepatitis B virus isolates from Malawian chronic carriers of the virus.Journal of Medical Virology2003; 69: 33–40.
36.
SugauchiF., ChutaputtiA., OritoE., KatoH., SuzukiS., UedaR., & MizokamiM.Hepatitis B virus genotypes and clinical manifestation among hepatitis B carriers in Thailand.Journal of Gastroenterology & Hepatology2002; 17: 671–676.
37.
Arauz-RuizP., NorderH., RobertsonB.H., & MagniusL.O.Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America.Journal of General Virology2002; 83: 2059–2073.
38.
KaoJ.H.Clinical relevance of hepatitis B viral genotypes: a case of deja vu?Journal of Gastroenterology & Hepatology2002; 17: 113–115.
39.
NorderH., CourouceA.M., CoursagetP., EchevarriaJ.M., LeeS.D., MushahwarI.K., RobertsonB.H., LocarniniS., & MagniusL.O.Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.Intervirology2004; 47: 289–309.
40.
MagniusL.O., & NorderH.Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene.Intervirology1995; 38: 24–34.
41.
WestlandC., DelaneyWt, YangH., ChenS.S., MarcellinP., HadziyannisS., GishR., FryJ., BrosgartC., GibbsC., MillerM., & XiongS.Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.Gastroenterology2003; 125: 107–116.
42.
ChuC.J., & LokA.S.Clinical significance of hepatitis B virus genotypes.Hepatology2002; 35: 1274–1276.
43.
ArankalleV.A., MurhekarK.M., GandheS.S., MurhekarM.V., RamdasiA.Y., PadbidriV.S., & SehgalS.C.Hepatitis B virus: predominance of genotype D in primitive tribes of the Andaman and Nicobar islands, India (1989–1999).Journal of General Virology2003; 84: 1915–1920.
44.
GandheS.S., ChadhaM.S., & ArankalleV.A.Hepatitis B virus genotypes and serotypes in western India: lack of clinical significance.Journal of Medical Virology2003; 69: 324–330.
KatoH., GishR.G., BzowejN., NewsomM., SugauchiF., TanakaY., KatoT., OritoE., UsudaS., UedaR., MiyakawaY., & MizokamiM.Eight genotypes (A–H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics.Journal of Medical Virology2004; 73: 516–521.
47.
NguyenM.H., & KeeffeE.B.Chronic hepatitis B and hepatitis C in Asian Americans.Reviews in Gastroenterological Disorders2003; 3: 125–134.
48.
ChuC.J., KeeffeE.B., HanS.H., PerrilloR.P., MinA.D., Soldevila-PicoC., CareyW., BrownR.S.Jr., LuketicV.A., TerraultN., & LokA.S.Hepatitis B virus genotypes in the United States: results of a nationwide study.Gastroenterology2003; 125: 444–451.
49.
MilichD., & LiangT.J.Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection.Hepatology2003; 38: 1075–1086.
50.
GuntherS., FischerL., PultI., SterneckM., & WillH.Naturally occurring variants of hepatitis B virus.Advances in Virus Research1999; 52: 25–137.
51.
ChuC.J., KeeffeE.B., HanS.H., PerrilloR.P., MinA.D., Soldevila-PicoC., CareyW., BrownR.S.Jr., LuketicV.A., TerraultN., & LokA.S.Prevalence of HBV precore/core promoter variants in the United States.Hepatology2003; 38: 619–628.
52.
YuenM.F., SablonE., WongD.K., YuanH.J., WongB.C., ChanA.O., & LaiC.L.Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation.Clinical Infectious Diseases2003; 37: 593–597.
53.
RizzettoM., VolpesR., & SmedileA.Response of pre-core mutant chronic hepatitis B infection to lamivudine.Journal of Medical Virology2000; 61: 398–402.
54.
ChinR., & LocarniniS.Treatment of chronic hepatitis B: current challenges and future directions.Reviews in Medical Virology2003; 13: 255–272.
55.
LaggetM., & RizzettoM.Current pharmacotherapy for the treatment of chronic hepatitis B.Expert Opinions in Pharmacotherapy2003; 4: 1821–1827.
56.
ColliA., MassironiS., & AnreolettiM.Interferon therapy in hepatitis B e antigen-negative chronic hepatitis B.Hepatology2003; 38: 779–780.
57.
YalcinK., DegertekinH., YildizF., & CelikY.Markers of disease activity in chronic hepatitis B virus infection.Clinical Investigative Medicine2003; 26: 27–34.
58.
KobayashiM., AraseY., IkedaK., TsubotaA., SuzukiY., SaitohS., SuzukiF., AkutaN., HosakaT., SomeyaT., MatsudaM., SatoJ., TakagiK., MiyakawaY., & KumadaH.Precore wild-type hepatitis B virus with G1896 in the resolution of persistent hepatitis B virus infection.Intervirology2003; 46: 157–163.
59.
LokA.S., AkarcaU., & GreeneS.Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal.Proceedings of the National Academy of Sciences, USA1994; 91: 4077–4081.
60.
GrandjacquesC., PradatP., StuyverL., ChevallierM., ChevallierP., PichoudC., MaisonnasM., TrepoC., & ZoulimF.Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity.Journal of Hepatology2000; 33: 430–439.
61.
JardiR., RodriguezF., ButiM., CostaX., ValdesA., AllendeH., SchaperM., GalimanyR., EstebanR., & GuardiaJ.Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers.Journal of Hepatology2004; 40: 507–514.
62.
BoninoF., & BrunettoM.R.Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview.Journal of Hepatology2003; 39: S160–S163.
63.
HadziyannisS.J., & VassilopoulosD.Hepatitis B e antigen-negative chronic hepatitis B.Hepatology2001; 34: 617–624.
64.
MayeratC., ManteganiA., SpertiniF., & FreiP.C.Mutations in the basal core promoter and precore/core gene of hepatitis B virus in patients with chronic active but not acute hepatitis B.European Journal of Clinical Microbiology & Infectious Diseases1999; 18: 871–878.
65.
KawaiK., HoriikeN., MichitakaK., & OnjiM.The effects of hepatitis B virus core promoter mutations on hepatitis B core antigen distribution in hepatocytes as detected by laser-assisted microdissection.Journal of Hepatology2003; 38: 635–641.
66.
HuntC.M., McGillJ.M., AllenM.I., & CondreayL.D.Clinical relevance of hepatitis B viral mutations.Hepatology2000; 31: 1037–1044.
67.
MarroneA., ZampinoR., LuongoG., UtiliR., KarayiannisP., & RuggieroG.Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection.Intervirology2003; 46: 222–226.
68.
ErhardtA., ReinekeU., BlondinD., GerlichW.H., AdamsO., HeintgesT., NiederauC., & HaussingerD.Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B.Hepatology2000; 31: 716–725.
69.
MilichD.R., SchodelF., HughesJ.L., JonesJ.E., & PetersonD.L.The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype.Journal of Virology1997; 71: 2192–2201.
70.
KaoJ.H., ChenP.J., LaiM.Y., & ChenD.S.Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers.Gastroenterology2003; 124: 327–334.
71.
HadziyannisS.J., PapatheodoridisG.V., DimouE., LarasA., & PapaioannouC.Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Hepatology2000; 32: 847–851.
72.
PumpensP., GrensE., & NassalM.Molecular epidemiology and immunology of hepatitis B virus infection – an update.Intervirology2002; 45: 218–232.
73.
LokA.S.Does interferon therapy for chronic hepatitis B reduce the risks of developing cirrhosis and hepatocellular carcinoma?Hepatology1995; 22: 1336–1338.
74.
BockC.T., TillmannH.L., MaschekH.J., MannsM.P., & TrautweinC.A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly.Gastroenterology1997; 113: 1976–1982.
75.
Le SeyecJ., ChouteauP., CannieI., Guguen-GuillouzoC., & GriponP.Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain.Journal of Virology1999; 73: 2052–2057.
76.
SugauchiF., OhnoT., OritoE., SakugawaH., IchidaT., KomatsuM., KuramitsuT., UedaR., MiyakawaY., & MizokamiM.Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease.Journal of Medical Virology2003; 70: 537–544.
77.
DingX., MizokamiM., GeX., OritoE., IinoS., UedaR., & NakanishiM.Different hepatitis B virus genotype distributions among asymptomatic carriers and patients with liver diseases in Nanning, southern China.Hepatology Research2002; 22: 37–44.
78.
YuenM.F., SablonE., YuanH.J., WongD.K., HuiC.K., WongB.C., ChanA.O., & LaiC.L.Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma.Hepatology2003; 37: 562–567.
79.
KobayashiM., AraseY., IkedaK., TsubotaA., SuzukiY., SaitohS., SuzukiF., AkutaN., SomeyaT., MatsudaM., SatoJ., & KumadaH.Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C.Journal of Gastroenterology2002; 37: 35–39.
80.
MayeratC., ManteganiA., & FreiP.C.Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection?Journal of Viral Hepatitis1999; 6: 299–304.
81.
ChuC.J., HussainM., & LokA.S.Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.Gastroenterology2002; 122: 1756–1762.
82.
KaoJ.H., ChenP.J., LaiM.Y., & ChenD.S.Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B.Gastroenterology2000; 118: 554–559.
83.
OritoE., IchidaT., SakugawaH., SataM., HoriikeN., HinoK., OkitaK., OkanoueT., IinoS., TanakaE., SuzukiK., WatanabeH., HigeS., & MizokamiM.Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan.Hepatology2001; 34: 590–594.
84.
FujieH., MoriyaK., ShintaniY., YotsuyanagiH., IinoS., & KoikeK.Hepatitis B virus genotypes and hepatocellular carcinoma in Japan.Gastroenterology2001; 120: 1564–1565.
85.
WaiC.T., ChuC.J., HussainM., & LokA.S.HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.Hepatology2002; 36: 1425–1430.
86.
KaoJ.H., WuN.H., ChenP.J., LaiM.Y., & ChenD.S.Hepatitis B genotypes and the response to interferon therapy.Journal of Hepatology2000; 33: 998–1002.
87.
FurusyoN., NakashimaH., KashiwagiK., KuboN., HayashidaK., UsudaS., MishiroS., KashiwagiS., & HayashiJ.Clinical outcomes of hepatitis B virus (HBV) genotypes B and C in Japanese patients with chronic HBV infection.American Journal of Tropical Medicine & Hygiene2002; 67: 151–157.
88.
KobayashiM., AraseY., IkedaK., TsubotaA., SuzukiY., SaitohS., SuzukiF., AkutaN., SomeyaT., MatsudaM., SatoJ., TakagiK., MiyakawaY., & KumadaH.Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan.Journal of Medical Virology2002; 68: 522–528.
89.
LiuX., & SchinaziR. F.Hepatitis B virus resistance to lamivudine and its clinical implications.Antiviral Chemistry & Chemotherapy2002; 13: 143–155.
90.
KaoJ.H., LiuC.J., & ChenD.S.Hepatitis B viral genotypes and lamivudine resistance.Journal of Hepatology2002; 36: 303–304.
91.
LaiC.L., ChienR.N., LeungN.W., ChangT.T., GuanR., TaiD.I., NgK.Y., WuP.C., DentJ.C., BarberJ., StephensonS.L., & GrayD. F.A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.New England Journal of Medicine1998; 339: 61–68.
92.
DienstagJ.L., SchiffE.R., WrightT.L., PerrilloR.P., HannH.W., GoodmanZ., CrowtherL., CondreayL.D., WoessnerM., RubinM., & BrownN.A.Lamivudine as initial treatment for chronic hepatitis B in the United States.New England Journal of Medicine1999; 341: 1256–1263.
93.
AkutaN., SuzukiF., KobayashiM., TsubotaA., SuzukiY., HosakaT., SomeyaT., SaitohS., AraseY., IkedaK., & KumadaH.The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.Journal of Hepatology2003; 38: 315–321.
94.
AyresA., BartholomeuszA., LauG., LamK.C., LeeJ.Y., & LocarniniS.Lamivudine and famciclovir resistant hepatitis B virus associated with fatal hepatic failure.Journal of Clinical Virology2003; 27: 111–116.
95.
PapatheodoridisG.V., DimouE., LarasA., PapadimitropoulosV., & HadziyannisS.J.Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.Hepatology2002; 36: 219–226.
96.
SuzukiF., TsubotaA., AraseY., SuzukiY., AkutaN., HosakaT., SomeyaT., KobayashiM., SaitohS., IkedaK., MatsudaM., SatohJ., TakagiK., & KumadaH.Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.Intervirology2003; 46: 182–189.
97.
PapatheodoridisG.V., DimouE., & PapadimitropoulosV.Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.American Journal of Gastroenterology2002; 97: 1618–1628.
98.
LeungN.W.Management of viral hepatitis C.Journal of Gastroenterology & Hepatology2002; 17 (Suppl): S146–S154.
99.
DelaneyW.E.4th, YangH., WestlandC.E., DasK., ArnoldE., GibbsC.S., MillerM.D., & XiongS.The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.Journal of Virology2003; 77: 11833–11841.
100.
ZollnerB., PetersenJ., SchroterM., LaufsR., SchoderV., & FeuchtH.H.20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.Lancet2001; 357: 934–935.
101.
ButiM., CotrinaM., ValdesA., JardiR., Rodriguez-FriasF., & EstebanR.Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?Journal of Hepatology2002; 36: 445–446.
102.
QaqishR.B., MattesK.A., & RitchieD.J.Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection.Clinical Therapeutics2003; 25: 3084–3099.
103.
DandoT., & PloskerG.Adefovir dipivoxil: a review of its use in chronic hepatitis B.Drugs2003; 63: 2215–2234.
104.
PetersM.G., Hann HwH., MartinP., HeathcoteE.J., BuggischP., RubinR., BourliereM., KowdleyK., TrepoC., Gray DfD., SullivanM., KleberK., EbrahimiR., XiongS., & BrosgartC.L.Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.Gastroenterology2004; 126: 91–101.
105.
AngusP., VaughanR., XiongS., YangH., DelaneyW., GibbsC., BrosgartC., ColledgeD., EdwardsR., AyresA., BartholomeuszA., & LocarniniS.Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.Gastroenterology2003; 125: 292–297.
106.
YadavV., & ChuC.K.Molecular mechanisms of adefovir sensitivity and resistance in HBV polymerase mutants: a molecular dynamics study.Bioorganic & Medicinal Chemistry Letters2004; 14: 4313–4317.
107.
KuoA., DienstagJ.L., & ChungR.T.Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.Clinical Gastroenterology & Hepatology2004; 2: 266–272.
108.
DoreG.J., CooperD.A., PozniakA.L., DeJesusE., ZhongL., MillerM.D., LuB., & ChengA.K.Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and experienced patients coinfected with HIV-1 and hepatitis B virus.Journal of Infectious Diseases2004; 189: 1185–1192.
109.
LadaO., BenhamouY., CahourA., KatlamaC., PoynardT., & ThibaultV.In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.Antiviral Therapy2004; 9: 353–363.
110.
KeeffeE.B., DieterichD.T., HanS.H., JacobsonI.M., MartinP., SchiffE.R., TobiasH., & WrightT.L.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States.Clincal Gastroenterology & Hepatology2004; 2: 87–106.
